Springhill Fund Asset Management HK Co Ltd Buys New Shares in Bicycle Therapeutics plc (NASDAQ:BCYC)

Springhill Fund Asset Management HK Co Ltd bought a new stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 116,400 shares of the company's stock, valued at approximately $1,630,000. Bicycle Therapeutics makes up about 2.6% of Springhill Fund Asset Management HK Co Ltd's holdings, making the stock its 14th biggest holding. Springhill Fund Asset Management HK Co Ltd owned about 0.17% of Bicycle Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after buying an additional 1,782 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after purchasing an additional 2,191 shares in the last quarter. Avior Wealth Management LLC bought a new position in shares of Bicycle Therapeutics during the fourth quarter worth about $57,000. Jane Street Group LLC grew its position in shares of Bicycle Therapeutics by 35.7% in the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock worth $457,000 after acquiring an additional 5,310 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Bicycle Therapeutics by 79.3% during the third quarter. Geode Capital Management LLC now owns 38,335 shares of the company's stock valued at $868,000 after purchasing an additional 16,958 shares during the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BCYC. HC Wainwright reaffirmed a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday. Stephens reissued an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. B. Riley dropped their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Finally, JMP Securities decreased their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.14.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ:BCYC traded up $0.06 during trading on Friday, reaching $6.59. The company had a trading volume of 119,000 shares, compared to its average volume of 393,131. Bicycle Therapeutics plc has a twelve month low of $6.10 and a twelve month high of $28.67. The firm has a market capitalization of $456.11 million, a PE ratio of -2.01 and a beta of 1.40. The firm's fifty day moving average is $10.01 and its 200 day moving average is $16.18.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. During the same period last year, the company posted ($1.16) EPS. The firm's quarterly revenue was down 30.2% on a year-over-year basis. Equities analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.